Pfizer Corporation

Agouron Pharmaceuticals, Inc.

Junhua Tao

Carlos Alberto Martinez

Shanghui Hu

Yves Dumond

William Eugene Tully

Patrick Kelleher

Steven Lee Bender

Srinivasan Babu

Michael J Melnick

Terence J Moran

Qingping Tian

Travis Paul Remarchuk

Raymond Dagnino, Jr

Naresh Nayyar

Lennert J Mitchell, Jr

Pei-Pei Kung

Materials and methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

Preparation of pregabalin and related compounds

Materials and Methods for preparing (S)-(+)-3-aminomethyl-5-methyl-hexanoic acid and structurally related compounds via enzymatic kinetic resolution are disclosed.

The invention relates to biocatalytic methods for preparing enantiomerically pure stereoisomers of 1-(2,6-dichloro-3-fluorophenyl)ethanol. Disclosed are methods of preparation of the desired (S)-enantiomer, which methods are based on a combination of enzymatic resolution, chemical esterification and chemical hydrolysis with inversion of 1-(2,6-dichloro-3-fluorophenyl)ethyl esters or stereoselective bio-reduction of 2,6-dichloro-3-fluoro-acetophenone with a biocatalyst such as an enzyme or a microorganism. The chiral (S)-enantiomer can be used in the synthesis of certain enantiomerically enriched, ether linked 2-aminopyridine compounds that potently inhibit auto-phosphorylation of human heptocyte growth factor receptor.

Enantioselective biotransformation for preparation of protein tyrosine kinase inhibitor intermediates

Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, as well as key intermediates useful in those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses.

Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates

Efficient synthetic routes for the preparation of rhinovirus protease inhibitors of formula I, as well as key intermediates useful in those synthetic routes. These compounds of formula I, as well as pharmaceutical compositions that contain these compounds, are suitable for treating patients or hosts infected with one or more picornaviruses

Growing community of inventors

San Diego, CA, United States of America

Junhua Tao